{"id":"W2344298048","doi":"10.1016/j.jval.2015.03.974","title":"Canadian Public Reimbursement of Subsequent Entry Biologics (Sebs) / Biosimilars","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Infliximab; Biosimilar; Reimbursement; Formulary; Medicine; Family medicine; Health care; Internal medicine; Disease; Political science","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002414876,0.0001600525,0.000408075,0.0003093568,0.00007172907,0.000008780177,0.0002745144,0.0003282424,0.0002152982],"category_scores_gemma":[0.0003895185,0.0001281582,0.00007338194,0.0004060728,0.0001930938,0.00003834222,0.0000616806,0.0003283655,0.00004007342],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006304943,"about_ca_system_score_gemma":0.001620595,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.09299151,"about_ca_topic_score_gemma":0.02157187,"domain_scores_codex":[0.9974294,0.0008562258,0.0006207881,0.0003057233,0.00005910863,0.0007288067],"domain_scores_gemma":[0.9990322,0.0001219238,0.0001705532,0.0003225448,0.00009741988,0.0002553785],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00048027,0.002048857,0.5377393,0.0006643149,0.0006198277,0.0001043392,0.002094769,0.0003889373,0.01646463,0.1530989,0.2045379,0.08175799],"study_design_scores_gemma":[0.003716655,0.002575788,0.0206564,0.0003471122,0.00004015691,0.00008269189,0.001693077,0.0003598275,0.02173176,0.009460282,0.9385576,0.0007786144],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7152494,0.05616772,0.0003880268,0.206684,0.006090959,0.002093785,0.000584818,0.0001604209,0.01258089],"genre_scores_gemma":[0.9933054,0.0008182275,0.001864722,0.003538596,0.00002865486,0.0000102202,0.00004616946,0.00001149797,0.0003764858],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7340198,"threshold_uncertainty_score":0.9962819,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1314074851867528,"score_gpt":0.3296436078192548,"score_spread":0.198236122632502,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}